LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic.

    Azapira, Negar / Pourjafar, Sarina / Habibi, Azam / Tayebi, Lobat / Keshtkar, Somayeh / Kaviani, Maryam

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

    2021  

    Abstract: ... derived extracellular vesicles as a new, safe, and effective therapeutic approach in the treatment ... Mesenchymal stromal cell-derived extracellular vesicles contain large amounts of proteins, messenger RNA, and microRNAs ... the pathogenesis of COVID-19 is not completely understood, and finding an effective new drug is still inconclusive ...

    Abstract The pandemic of severe acute respiratory syndrome coronavirus-2 infection has prompted the urgent need for novel therapeutic approaches, especially for patients in critically severe conditions. To date, the pathogenesis of COVID-19 is not completely understood, and finding an effective new drug is still inconclusive. Mesenchymal stromal cell-derived extracellular vesicles contain large amounts of proteins, messenger RNA, and microRNAs that act as vehicles that transfer the cargo between cells. These nanotherapeutic materials exert anti-inflammatory effects on the immune system, which are necessary for subsidence of acute inflammation and promotion of tissue repair and regeneration. Therefore, the consideration of mesenchymal stromal cell-derived extracellular vesicles as a new, safe, and effective therapeutic approach in the treatment of COVID-19 pneumonia is suggested.
    Language English
    Publishing date 2021-02-23
    Publishing country Turkey
    Document type Journal Article ; Review
    ZDB-ID 2396778-X
    ISSN 2146-8427 ; 1304-0855
    ISSN (online) 2146-8427
    ISSN 1304-0855
    DOI 10.6002/ect.2020.0296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6632: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment.

    Huang, Yuling / Li, Xin / Yang, Lina

    Stem cell research & therapy

    2022  Volume 13, Issue 1, Page(s) 410

    Abstract: ... extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular ... some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity ... Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole ...

    Abstract Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole world, seriously affecting global economic growth, and threatening people's lives and health. At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed.
    MeSH term(s) COVID-19/drug therapy ; COVID-19/therapy ; Coronavirus Infections/therapy ; Extracellular Vesicles ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stem Cells
    Language English
    Publishing date 2022-08-12
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2548671-8
    ISSN 1757-6512 ; 1757-6512
    ISSN (online) 1757-6512
    ISSN 1757-6512
    DOI 10.1186/s13287-022-03034-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases

    Natalia Yudintceva / Natalia Mikhailova / Viacheslav Fedorov / Konstantin Samochernych / Tatiana Vinogradova / Alexandr Muraviov / Maxim Shevtsov

    Bioengineering, Vol 9, Iss 662, p

    From Basic Research to Clinical Practice

    2022  Volume 662

    Abstract: ... to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic ... derived extracellular vesicles (MSC-EVs) in the combined treatment of infectious diseases. Application ... with antiviral drugs. Employment of MSC-derived EVs represents a more promising strategy for cell-free treatment ...

    Abstract Mesenchymal stem cells (MSCs) are attractive in various fields of regenerative medicine due to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic have given impetus to the development of cell therapy for infectious diseases. The aim of this review was to systematize scientific data on the applications of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) in the combined treatment of infectious diseases. Application of MSCs and MSC-EVs in the treatment of infectious diseases has immunomodulatory, anti-inflammatory, and antibacterial effects, and also promotes the restoration of the epithelium and stimulates tissue regeneration. The use of MSC-EVs is a promising cell-free treatment strategy that allows solving the problems associated with the safety of cell therapy and increasing its effectiveness. In this review, experimental data and clinical trials based on MSCs and MSC-EVs for the treatment of infectious diseases are presented. MSCs and MSC-EVs can be a promising tool for the treatment of various infectious diseases, particularly in combination with antiviral drugs. Employment of MSC-derived EVs represents a more promising strategy for cell-free treatment, demonstrating a high therapeutic potential in preclinical studies.
    Keywords mesenchymal stem cells ; extracellular vesicles ; regenerative medicine ; tissue engineering ; infectious diseases ; COVID-19 ; Technology ; T ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2022-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.

    Yudintceva, Natalia / Mikhailova, Natalia / Fedorov, Viacheslav / Samochernych, Konstantin / Vinogradova, Tatiana / Muraviov, Alexandr / Shevtsov, Maxim

    Bioengineering (Basel, Switzerland)

    2022  Volume 9, Issue 11

    Abstract: ... to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic ... derived extracellular vesicles (MSC-EVs) in the combined treatment of infectious diseases. Application ... with antiviral drugs. Employment of MSC-derived EVs represents a more promising strategy for cell-free treatment ...

    Abstract Mesenchymal stem cells (MSCs) are attractive in various fields of regenerative medicine due to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic have given impetus to the development of cell therapy for infectious diseases. The aim of this review was to systematize scientific data on the applications of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) in the combined treatment of infectious diseases. Application of MSCs and MSC-EVs in the treatment of infectious diseases has immunomodulatory, anti-inflammatory, and antibacterial effects, and also promotes the restoration of the epithelium and stimulates tissue regeneration. The use of MSC-EVs is a promising cell-free treatment strategy that allows solving the problems associated with the safety of cell therapy and increasing its effectiveness. In this review, experimental data and clinical trials based on MSCs and MSC-EVs for the treatment of infectious diseases are presented. MSCs and MSC-EVs can be a promising tool for the treatment of various infectious diseases, particularly in combination with antiviral drugs. Employment of MSC-derived EVs represents a more promising strategy for cell-free treatment, demonstrating a high therapeutic potential in preclinical studies.
    Language English
    Publishing date 2022-11-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2746191-9
    ISSN 2306-5354
    ISSN 2306-5354
    DOI 10.3390/bioengineering9110662
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.

    Raghav, Alok / Khan, Zeeshan Ahmad / Upadhayay, Viabhav Kumar / Tripathi, Prashant / Gautam, Kirti Amresh / Mishra, Brijesh Kumar / Ahmad, Jamal / Jeong, Goo-Bo

    Cells

    2021  Volume 10, Issue 3

    Abstract: ... In this context, mesenchymal stem cell (MSC)-derived exosomes can serve as an immunomodulation treatment for COVID ... of using exosomes derived from mesenchymal stem cells in management of the co-morbidities associated ... 19 infection. The COVID-19 pandemic represents one of the worst global threats in the 21st century ...

    Abstract The novel coronavirus severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) is responsible for COVID-19 infection. The COVID-19 pandemic represents one of the worst global threats in the 21st century since World War II. This pandemic has led to a worldwide economic recession and crisis due to lockdown. Biomedical researchers, pharmaceutical companies, and premier institutes throughout the world are claiming that new clinical trials are in progress. During the severe phase of this disease, mechanical ventilators are used to assist in the management of outcomes; however, their use can lead to the development of pneumonia. In this context, mesenchymal stem cell (MSC)-derived exosomes can serve as an immunomodulation treatment for COVID-19 patients. Exosomes possess anti-inflammatory, pro-angiogenic, and immunomodulatory properties that can be explored in an effort to improve the outcomes of SARS-CoV-2-infected patients. Currently, only one ongoing clinical trial (NCT04276987) is specifically exploring the use of MSC-derived exosomes as a therapy to treat SARS-CoV-2-associated pneumonia. The purpose of this review is to provide insights of using exosomes derived from mesenchymal stem cells in management of the co-morbidities associated with SARS-CoV-2-infected persons in direction of improving their health outcome. There is limited knowledge of using exosomes in SARS-CoV-2; the clinicians and researchers should exploit exosomes as therapeutic regime.
    MeSH term(s) COVID-19/complications ; COVID-19/metabolism ; COVID-19/pathology ; COVID-19/therapy ; Cytokines/metabolism ; Cytokines/pharmacology ; Exosomes/chemistry ; Exosomes/genetics ; Exosomes/metabolism ; Extracellular Vesicles/metabolism ; Humans ; Immunomodulation ; Inflammation/immunology ; Inflammation/therapy ; Inflammation/virology ; Mesenchymal Stem Cells/immunology ; Mesenchymal Stem Cells/metabolism ; Neovascularization, Physiologic/immunology ; Pneumonia, Viral/complications ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; Respiratory Tract Infections/complications ; Respiratory Tract Infections/therapy ; Respiratory Tract Infections/virology
    Chemical Substances Cytokines
    Language English
    Publishing date 2021-03-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells10030587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment.

    Chinnici, Cinzia Maria / Russelli, Giovanna / Bulati, Matteo / Miceli, Vitale / Gallo, Alessia / Busà, Rosalia / Tinnirello, Rosaria / Conaldi, Pier Giulio / Iannolo, Gioacchin

    World journal of gastroenterology

    2021  Volume 27, Issue 17, Page(s) 1905–1919

    Abstract: ... implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment, and emphasize ... from their secretome, including the extracellular vesicles, representing a promising approach in regenerative medicine ... leading to death in coronavirus disease 2019 (COVID-19) patients. We herein summarize the current ...

    Abstract Due to their immunomodulatory potential and release of trophic factors that promote healing, mesenchymal stromal cells (MSCs) are considered important players in tissue homeostasis and regeneration. MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage. Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome, including the extracellular vesicles, representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis. The recent outbreak of respiratory syndrome coronavirus, caused by the newly identified agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has forced scientists worldwide to use all available instruments to fight the infection, including the inflammatory cascade caused by this pandemic disease. The use of MSCs is a valid approach to combat organ inflammation in different compartments. In addition to the lungs, which are considered the main inflammatory target for this virus, other organs are compromised by the infection. In particular, the liver is involved in the inflammatory response to SARS-CoV-2 infection, which causes organ failure, leading to death in coronavirus disease 2019 (COVID-19) patients. We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment, and emphasize the potential of MSC-based therapy in this clinical setting.
    MeSH term(s) COVID-19/drug therapy ; Humans ; Liver Failure ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stem Cells ; SARS-CoV-2
    Language English
    Publishing date 2021-05-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v27.i17.1905
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment

    Yuling Huang / Xin Li / Lina Yang

    Stem Cell Research & Therapy, Vol 13, Iss 1, Pp 1-

    2022  Volume 12

    Abstract: ... and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized ... At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral ... of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs ...

    Abstract Abstract Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole world, seriously affecting global economic growth, and threatening people’s lives and health. At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed.
    Keywords Mesenchymal stem cells ; Small extracellular vesicles ; COVID-19 ; Molecular mechanism ; Medicine (General) ; R5-920 ; Biochemistry ; QD415-436
    Language English
    Publishing date 2022-08-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients

    Alok Raghav / Zeeshan Ahmad Khan / Viabhav Kumar Upadhayay / Prashant Tripathi / Kirti Amresh Gautam / Brijesh Kumar Mishra / Jamal Ahmad / Goo-Bo Jeong

    Cells, Vol 10, Iss 587, p

    2021  Volume 587

    Abstract: ... In this context, mesenchymal stem cell (MSC)-derived exosomes can serve as an immunomodulation treatment for COVID ... of using exosomes derived from mesenchymal stem cells in management of the co-morbidities associated ... 19 infection. The COVID-19 pandemic represents one of the worst global threats in the 21st century ...

    Abstract The novel coronavirus severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) is responsible for COVID-19 infection. The COVID-19 pandemic represents one of the worst global threats in the 21st century since World War II. This pandemic has led to a worldwide economic recession and crisis due to lockdown. Biomedical researchers, pharmaceutical companies, and premier institutes throughout the world are claiming that new clinical trials are in progress. During the severe phase of this disease, mechanical ventilators are used to assist in the management of outcomes; however, their use can lead to the development of pneumonia. In this context, mesenchymal stem cell (MSC)-derived exosomes can serve as an immunomodulation treatment for COVID-19 patients. Exosomes possess anti-inflammatory, pro-angiogenic, and immunomodulatory properties that can be explored in an effort to improve the outcomes of SARS-CoV-2-infected patients. Currently, only one ongoing clinical trial (NCT04276987) is specifically exploring the use of MSC-derived exosomes as a therapy to treat SARS-CoV-2-associated pneumonia. The purpose of this review is to provide insights of using exosomes derived from mesenchymal stem cells in management of the co-morbidities associated with SARS-CoV-2-infected persons in direction of improving their health outcome. There is limited knowledge of using exosomes in SARS-CoV-2; the clinicians and researchers should exploit exosomes as therapeutic regime.
    Keywords exosomes ; SARS-CoV-2 ; COVID-19 ; mesenchymal stem cells ; anti-inflammatory ; extracellular vesicles ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top